# A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

> **NCT02555150** · PHASE3 · COMPLETED · sponsor: **Rhodes Pharmaceuticals, L.P.** · enrollment: 40 (estimated)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** PRC-063
- **DRUG:** lisdexamfetamine dimesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02555150
- **Lead sponsor:** Rhodes Pharmaceuticals, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555150, "A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02555150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*